10 November 2022 - - US-based clinical stage eye care pharmaceutical company MediPrint Ophthalmics has initiated its SIGHT-2 dose-finding Phase 2b study for its proprietary drug-eluting contact lens for glaucoma, the company said.

This is the second study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating mild to moderate glaucoma and ocular hypertension.

SIGHT-2 is designed to assess dose optimization for the company's lead asset, LL-BMT1, a drug-eluting contact lens to treat glaucoma, and is preceded by the successful completion of the company's SIGHT-1 study that validated the MediPrint process and contact lenses for treating human subjects.

The concluded SIGHT-1 trial successfully achieved its objectives by showing a favorable safety and tolerability profile and demonstrated a sustained efficacy signal from a single dose.

Consequently, MediPrint is proceeding with this previously announced SIGHT-2 study for LL-BMT1, a weekly medicated contact lens releasing bimatoprost to treat open angle glaucoma and ocular hypertension. Patient enrollment is slated to begin imminently.

MediPrint has retained CBCC Global Research to facilitate the regulatory, clinical operations, data management and biometric services for the SIGHT-2 study.

The company also announces a move into its new San Diego headquarters. The larger facility will house corporate offices along with research and development functions and an ISO compliant GMP manufacturing facility.

The new building and larger space will facilitate MediPrint scaling its current and future pipeline and is equipped to allow for developing both clinical and commercial stage product.

MediPrint Ophthalmics is an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life by developing and commercializing a proprietary contact lens based ocular drug delivery portfolio.

There are over 40m soft contact lens wearers in the United States alone and most of them will develop some eye disease or condition in their lifetime.

Treating their disease or condition with eye drops is inconvenient and frustrating, leading ms to become non-compliant or to be forced to drop out of contact lens wear.

The company's goal is to offer new treatment options that allow millions of patients to continue wearing their contact lens while the lens correcting their vision also delivers drugs to treat their underlying disease or condition.

The company is currently advancing its lead asset, a unique and complete glaucoma treatment, to the clinic while continuing to build out its product portfolio for dry eye and for allergy, and subsequently for other anterior and posterior segment conditions.

Approximately 5% of glaucoma patients in the United States wear contact lenses and MediPrint's innovative drug-eluting, comfort-enhancing, preservative-free contact lens may be an ideal treatment option for them.

MediPrint Ophthalmics' patented MediPrint process offers a unique value proposition for patients, practitioners, strategic partners, and payers.

CBCC Global Research is a full-service, specialty contract research organization offering a wide variety of clinical research services for the advancement of clinical development programs in Ophthalmology, Oncology, Neurology, Psychiatry and other therapeutic areas.

CBCC offers end-to-end services for clinical trials, including clinical operations, site management, safety management, clinical data management and statistical analysis and medical and scientific writing.